Could novel gel therapeutic set new standard of care in oncology?

New interim results from a Phase IIa trial suggest that a gel formulation could address skin toxicities (skin, scalp, nails) associated with epidermal growth factor receptor inhibitors (EGFRi) as a cancer treatment.